Form 4: Kymera COO Executes Planned Stock Sales
Statement of Changes in Beneficial Ownership
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick sold 17,184 shares of common stock to cover tax obligations and pursuant to a Rule 10b5-1 trading plan.
Summary
- Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics, Inc., reported the sale of 17,184 shares of common stock.
- Transactions occurred on May 26 and May 27, 2026.
- A portion of the shares (4,054) were sold to satisfy mandatory tax withholding obligations related to the vesting of restricted stock units.
- The remaining 13,130 shares were sold pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
- Following these transactions, the reporting person retains 44,018 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and partially mandated by tax obligations, carrying no signal of negative internal sentiment.
Positives
- The sales were conducted automatically to satisfy tax obligations or through a pre-established Rule 10b5-1 trading plan, indicating these were not discretionary market-timing trades.
Negatives
- The reduction in the executive's direct equity stake in the company.
Risks
- Market perception of insider selling, even when conducted via pre-planned arrangements.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via Rule 10b5-1 plans is standard practice in the biotechnology sector for executives to manage tax liabilities and diversify personal holdings without triggering market concerns regarding non-public information.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is a best-practice standard for corporate officers to ensure compliance with SEC regulations while liquidating equity compensation.
Stakeholder Impact
- Minimal impact on shareholders as the sales were pre-planned and systematic.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 2025-12-10 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2026-05-26 | Earliest transaction date for the reported sales. |
| 2026-05-27 | Final transaction date and filing date of the Form 4. |
Keywords
Kymera Therapeutics, KYMR, Insider Trading, Form 4, Biotech, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.